



## Company Overview

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Boulder, Colorado, with manufacturing operations in Jalisco, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.

## Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results

Feb 10 2026, 4:10 PM EST

## Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development

Jan 28 2026, 4:15 PM EST

## National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Nov 13 2025, 8:30 AM EST

## Stock Overview

Symbol	SNOA
Exchange	Nasdaq
Market Cap	4.78m
Last Price	\$2.81
52-Week	\$1.75 - \$6.9199

## Investor Relations

T: 470-938-1011  
[ir@sonomapharma.com](mailto:ir@sonomapharma.com)

02/10/2026 09:00 PM EST

## Management Team

### Amy Trombly

Chief Executive Officer

### Jerry Dvonch

Chief Financial Officer

### Arturo Angel

Senior Vice President of Regulatory, Quality and Product Development

## Sonoma Pharmaceuticals, Inc.

5445 Conestoga Court  
Suite 150  
Boulder, CO 80301

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.